The phase 3 trial was investigating the vibostolimab and pembrolizumab combination with chemotherapy for first-line treatment of extensive-stage small cell lung cancer.
Merck’s investigational drug for chronic cough is one step closer to coming to market after receiving a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use.
Merck has entered into a voluntary licensing agreement to allow the production of its investigational COVID-19 antiviral molnupiravir by drugmakers in 105 low- and middle-income countries.
The home, built as a partnership between Merck, Habitat for Humanity Detroit, the Asthma and Allergy Foundation of America, and HGTV, is for a Detroit family with asthma.
Read MoreFollowing Katrina, children in New Orleans demonstrated increased sensitivities to environmental asthma triggersputting them at risk for more severe asthma symptoms and attacks.
Read More